An antibody or antigen-binding fragment thereof specifically binding to galectin 3-binding protein (LGALS3BP), and a use thereof, is described. The antibody or antigen-binding fragment thereof may comprise heavy chain CDRs and light chain CDRs of specific sequences. The antibody specifically binding to LGALS3BP has been found to inhibit cancer growth and metastasis in an animal model with cancer and may be effective for alleviating or treating cancer.